Michael Berry
Chief Tech/Sci/R&D Officer en EVEREST MEDICINES LIMITED .
Perfil
Michael Berry is currently the Chief Technology Officer at Everest Medicines Ltd.
He previously worked as the Senior Director of Bioprocess Development at Portola Pharmaceuticals, Director at ARCA biopharma, Director of Manufacturing Sciences & Technology at Novartis Vaccines & Diagnostics SL, and Vice President at Dynavax Technologies Corp.
He is also the Chief Technical Operations Officer at Clover Biopharmaceuticals Ltd.
Berry received his undergraduate degree from De Montfort University, his graduate degree from The University of Manchester, and his doctorate from the University of Manitoba.
Cargos activos de Michael Berry
| Empresas | Cargo | Inicio |
|---|---|---|
| EVEREST MEDICINES LIMITED | Chief Tech/Sci/R&D Officer | 15/06/2023 |
Antiguos cargos conocidos de Michael Berry.
| Empresas | Cargo | Fin |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/08/2017 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2015 |
| Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | 01/09/2013 |
| ARCA BIOPHARMA, INC. | Director/Board Member | 01/05/2009 |
| CLOVER BIOPHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | - |
Formación de Michael Berry.
| The University of Manchester | Graduate Degree |
| University of Manitoba | Doctorate Degree |
| De Montfort University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ARCA BIOPHARMA, INC. | Health Technology |
| EVEREST MEDICINES LIMITED | Health Technology |
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Novartis Vaccines & Diagnostics SL |
- Bolsa de valores
- Insiders
- Michael Berry
